PF-Atlas › Clinical Trials › NCT03258424

Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis on KALYDECO® as Background Therapy

PTI-428 · Phase 1

Registry ID

NCT03258424

Phase

Phase 1

Status

Completed

Drug / intervention

PTI-428

Sponsor

Proteostasis Therapeutics, Inc.

Start

2017-07-28

About this trial

PTI-428 is evaluated in NCT03258424, a Phase 1 idiopathic pulmonary fibrosis study sponsored by Proteostasis Therapeutics, Inc.. Current status: Completed.

View NCT03258424 on ClinicalTrials.gov →

Explore related

All PTI-428 trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT03258424 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.